Fig. 4
Impact of amplifications in RAD21 and HGF on telomeric content. A Pie chart showing the prevalence of amplifications across all RAD21 alterations within prostate acinar adenocarcinoma, lung adenocarcinoma, breast carcinoma (nos), breast invasive lobular carcinoma, and breast invasive ductal carcinoma. B Alluvial plot depicting count of samples with co-amplifications in LYN, RAD21, and MYC within prostate acinar adenocarcinoma, lung adenocarcinoma, breast carcinoma (nos), breast invasive lobular carcinoma, and breast invasive ductal carcinoma samples. Colors of the streams were used to distinguish between the groups. AMP, amplified, NON AMP, non-amplified. C. Boxplot showing the impact of RAD21 and/or MYC amplifications on telomeric content of samples pan-cancer. **** denotes p<0.0001. D Analysis of enrichment for high telomeric content in samples with amplifications across chromosome bands in chr8q. E Pie chart showing the prevalence of amplifications within all HGF alterations within brain glioblastoma, prostate acinar adenocarcinoma, and kidney clear cell carcinoma. F Alluvial plot depicting count of samples with co-amplifications in HGF and CDK6 within brain glioblastoma, prostate acinar adenocarcinoma, and kidney clear cell carcinoma. AMP, amplified; NON-AMP, non-amplified. G Boxplot showing the impact of amplifications of HGF and/or CDK6 on telomeric content of samples pan-cancer. **** denotes p<0.0001. H Boxplot showing log10 TERRA levels in samples with alterations in ATRX, DAXX, HGF, RAD21, and those lacking alterations in any one of these genes (WT). Only comparisons against WT are shown. ** denotes p<0.01 and **** denotes p<0.0001. TERRA, Telomeric Repeat-containing RNA